UTILITY OF A PROLIFERATION MARKER IN DISTINGUISHING BETWEEN BENIGN NEVOCELLULAR NEVI AND NEVOCELLULAR NEVUS-LIKE LESIONS WITH MALIGNANT PROPERTIES

被引：25

作者：

KANTER, L ^{[1
]}

BLEGEN, H ^{[1
]}

WEJDE, J ^{[1
]}

LAGERLOF, B ^{[1
]}

LARSSON, O ^{[1
]}

机构：

[1] KAROLINSKA HOSP,DEPT TUMOR PATHOL,S-17176 STOCKHOLM,SWEDEN

来源：

MELANOMA RESEARCH | 1995年 / 5卷 / 05期

关键词：

BENIGN NEVOCELLULAR NEVUS; MIB1; MALIGNANT NEVOCELLULAR NEVUS-LIKE LESIONS; MELANOMA; PROLIFERATION MARKER;

D O I：

10.1097/00008390-199510000-00007

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In the present study we have investigated the utility of the proliferation marker MIB1 in distinguishing between benign naevocellular naevi and naevocellular naevus-like lesions with malignant potential, Percentages of MIB1 immunoreactivity in the intradermal portion of the lesions were determined. In benign congenital and acquired naevi, as well as in dysplastic naevi, there was no or only a slight intradermal melanocytic proliferation (0-2%), whereas vertical growth phase melanomas exhibited a substantial proliferative activity (11-48%). In five cases of naevus-like lesions, which had all relapsed as unmistakable malignant melanomas (locally or metastatically) after primary surgery, there was also clear proliferative activity (9-67%). Our findings suggest that MIB1 may be a useful tool in the routine histopathological examination of problematic naevocellular lesions.

引用

页码：345 / 350

页数：6

共 15 条

[1]

Herlyn M., Clark W.H., Rodeck U., Et al., Biology of disease. Tumour progression in human melanocytes, Lab Invest, 56, pp. 461-474, (1987)

[2]

Reintgen D.S., McCarty K.S., Woodard B., Et al., Metastatic malignant melanoma with an unknown primary, Surg Gynecol Obstet, 156, pp. 335-340, (1983)

[3]

Reed R.J., Minimal deviation melanoma, Pathology and Recognition of Malignant Melanoma, pp. 110-152, (1988)

[4]

Mihm M.C., Googe P.B., Problematic Pigmented Lesions: A Case Method Approach, (1990)

[5]

Gerdes J., Lemke H., Baisch H., Et al., Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67, J Immunol, 133, pp. 1710-1715, (1984)

[6]

Scott R.J., Hall P.A., Haidane J.S., Et al., A comparison of immunohistochemical markers of cell proliferation with experimentally determined growth fraction, J Pathol, 165, pp. 173-178, (1991)

[7]

Cattoretti G., Becker M.H.G., Key G., Et al., Monoclonal antibodies against recombinant parts of thr Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections, J Pathol, 168, pp. 357-363, (1992)

[8]

Key G., Becker M.H.G., Baron B., Et al., New Ki-67-equivalent murine antibodies (MIB1-3) generated against bacterially expressed parts of the Ki-67 cDNA containing three 62 base pair repetitive elements encoding for the Ki-67 epitope, Lab Invest, 68, pp. 629-636, (1993)

[9]

Orchard G., Wilson Jones E., Immunohistochemistry in the diagnosis of malignant melanoma, Br J Biomed Sci, 51, pp. 44-56, (1994)

[10]

Girod S.C., Groth W., Junk M., Et al., P53 and PCNA expression in malignant melanomas of the head and neck, Pigment Cell Res, 7, pp. 354-357, (1994)

← 1 2 →